Press Releases Items Per Page 102550 Year None2023202220212020201920182017201620152014 09-05-2023 Daré Bioscience Completes Previously Announced Equity Financing 08-30-2023 Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules 08-10-2023 Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update 08-09-2023 Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings 08-03-2023 Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023 07-31-2023 Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth 07-11-2023 Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems 07-11-2023 Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women 07-06-2023 Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder 07-05-2023 Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Displaying 11 - 20 of 39
08-30-2023 Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
08-10-2023 Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
08-09-2023 Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
08-03-2023 Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
07-31-2023 Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
07-11-2023 Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
07-11-2023 Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
07-06-2023 Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
07-05-2023 Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
